Favor broad healthcare ETFs over high-flying biotech
Investors were advised to favor diversified healthcare ETFs like XLV over chasing high-flying single-stock biotech runners like Moderna.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.